Bladder Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Bladder Cancer stocks.

Bladder Cancer Stocks Recent News

Date Stock Title
May 17 AEZS Aeterna Zentaris Finalizes Some Details for Ceapro Merger
May 17 AEZS Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
May 15 BCAB BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
May 15 AEZS Aeterna Zentaris GAAP EPS of -$4.74
May 15 AEZS MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden
May 15 BCAB BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
May 14 AEZS Aeterna Zentaris Reports First Quarter 2024 Financial Results
May 14 BCAB BioAtla GAAP EPS of -$0.48 beats by $0.06
May 14 BCAB BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 14 ACRV Acrivon Therapeutics GAAP EPS of -$0.73 beats by $0.11
May 14 ACRV Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14 URGN UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
May 13 URGN UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
May 13 URGN UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
May 13 TYRA Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
May 13 URGN UroGen Pharma GAAP EPS of -$0.97 misses by $0.08, revenue of $18.78M misses by $2.61M
May 13 URGN UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 12 URGN Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
Bladder Cancer

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. Symptoms include blood in the urine, pain with urination, and low back pain.Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals. The most common type is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma. Diagnosis is typically by cystoscopy with tissue biopsies. Staging of the cancer is typically determined by medical imaging such as CT scan and bone scan.Treatment depends on the stage of the cancer. It may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy. Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion. Typical five-year survival rates in the United States are 77%.Bladder cancer, as of 2015, affects about 3.4 million people globally with 430,000 new cases a year. In 2015 it resulted in 188,000 deaths. Age of onset is most often between 65 and 85 years of age. Males are more often affected than females. In the United States in 2018 81,000 cases and 17,000 deaths are expected making it the 6th most common type of cancer in the region.

Browse All Tags